Antibodies targeting the S100 protein and their use
Antibodies targeting S100A8/S100A9 heterooligomers provide a more effective treatment for inflammatory and autoimmune diseases and leukemia by inhibiting protein receptor binding, addressing the limitations of current small molecule inhibitors.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
- Filing Date
- 2024-05-10
- Publication Date
- 2026-06-16
AI Technical Summary
Current small molecule inhibitors, such as quinoline-3-carboxamide analogues, are not effective in inhibiting the binding of S100A8/A9 proteins to their receptors, leading to inadequate treatment outcomes for inflammatory and autoimmune diseases, leukemia, and myelodysplastic syndromes.
Development of antibodies or antigen-binding fragments that specifically target S100A8/S100A9 heterooligomers, including S100A8/S100A9 heterodimers, with high binding affinity and specificity, which can be used to treat diseases associated with S100 proteins.
The antibodies effectively inhibit the binding of S100A8/S100A9 proteins to their receptors, providing a more targeted approach to treating inflammatory and autoimmune diseases, leukemia, and myelodysplastic syndromes, including conditions like acute myeloid leukemia and chronic lymphocytic leukemia.
Smart Images
Figure 2026519503000001_ABST